Back to Browse Journals » Vascular Health and Risk Management » Volume 5

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man

Authors Alessandra Del Fiorentino, Silvana Cianchetti, Alessandro Celi, Giulia Dell’Omo, Roberto Pedrinelli

Published 8 February 2009 Volume 2009:5 Pages 233—242


Review by Single-blind

Peer reviewer comments 4

Alessandra Del Fiorentino, Silvana Cianchetti, Alessandro Celi, Giulia Dell’Omo, Roberto Pedrinelli

Dipartimento Cardio Toracico e Vascolare, Università di Pisa, Italy

Abstract: Anti-inflammatory properties may contribute to the pharmacological effects of angiotensin II receptor blockers (ARBs), a leading therapeutic class in the management of hypertension and related cardiovascular and renal diseases. That possibility, supported by consistent evidence from in-vitro and animal studies showing pro-inflammatory properties of angiotensin II, has been evaluated clinically by measuring the effect of ARBs on C-reactive protein and other circulating indices of inflammation (e-selectin, adhesion molecules, interleukin-6, tissue necrosis factor-alpha, monocyte chemoattractant protein-1) of potential clinical relevance, a body of evidence that this paper aims to review.

Keywords: renin–angiotensin system, angiotensin II type 1 receptor blockers, vascular inflammation, C-reactive protein, circulating inflammatory markers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Lack of a relationship between circulating gamma-glutamyltransferase levels and carotid intima media thickness in hypertensive and diabetic patients

Nuti M, Spontoni P, Grigoratos C, Dell'Omo G, Balbarini A, Pedrinelli R

Vascular Health and Risk Management 2012, 8:275-281

Published Date: 1 May 2012

Readers of this article also read:

Nanopharmacology in translational hematology and oncology

Tomuleasa C, Braicu C, Irimie A, Craciun L, Berindan-Neagoe I

International Journal of Nanomedicine 2014, 9:3465-3479

Published Date: 22 July 2014

Update on neuromyelitis optica: natural history and management

Jindahra P, Plant GT

Eye and Brain 2012, 4:27-41

Published Date: 28 March 2012

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma

Jain S, Diefenbach C, Zain J, O'Connor OA

Core Evidence 2011, 6:43-57

Published Date: 4 April 2011

Management of high-risk popliteal vascular blunt trauma: clinical experience with 62 cases

Ali Pourzand, Bassir A Fakhri, Ramin Azhough, et al

Vascular Health and Risk Management 2010, 6:613-618

Published Date: 14 July 2010

Heart rate control with adrenergic blockade: Clinical outcomes in cardiovascular medicine

David Feldman, Terry S Elton, Doron M Menachemi, et al

Vascular Health and Risk Management 2010, 6:387-397

Published Date: 24 May 2010

Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies

François Schiele

Vascular Health and Risk Management 2010, 6:179-187

Published Date: 26 March 2010

Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India

Krishna K Sharma, Rajeev Gupta, Aachu Agrawal, et al

Vascular Health and Risk Management 2009, 5:1007-1014

Published Date: 20 November 2009

Primary omental hydatid cyst

Halil Alis, Selin Kapan, Osman Öner, Aliye Soylu, Kemal Dolay, et al

International Medical Case Reports Journal 2009, 2:7-10

Published Date: 26 February 2009